Opinion

Video

Primary Differences in the Toxicity Profiles of Abemaciclib and Ribociclib

A panel of experts compare the toxicity profiles of abemaciclib and ribociclib.

Video content above is prompted by the following questions:

  • What are the primary differences in the toxicity profiles of abemaciclib and ribociclib when used in the adjuvant setting, and how are these prioritized when selecting a CDK4/6 inhibitor?
    • Discuss the recent publication of long-term patient-reported outcomes with adjuvant abemaciclib.

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
Michael Hassett, MD, MPH, Dana-Farber Cancer Institute
Rebecca Chacko, MD.
Rebecca Chacko, MD, breast medical oncologist at Henry Ford
4 experts in this video
4 experts in this video
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo